Nasdaq · CIK 0001339005
FEMY FEMASYS INC
Insider trading from SEC Form 4. Last filing Aug 11, 2026. Close $1.75 on Oct 12, 2026, 0% from the 52-week low and -92% from the high.
In brief
FEMASYS INC (FEMY) has 39 SEC Form 4 filings on file from 11 insiders, the latest filed on Aug 11, 2026. In the last 90 days insiders made 5 open-market buys worth $134k and 0 open-market sells worth $0, net +$134k.
5 open-market trades have been scored at FEMY. The newest: John Charles Canning (Chief Operating Officer) bought $14k of stock on Aug 7, 2026, filed Aug 11, 2026, scored 43 (moderate). The largest of the 5 shown: Dov Elefant (Chief Financial Officer) bought $50k on Aug 7, 2026, scored 52 (moderate). 5 insiders bought within 14 days of each other around Aug 7, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at FEMASYS INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | John Charles Canning Chief Operating Officer buy | $14k 4,375 shares | - | - | |
| 52Moderate | Dov Elefant Chief Financial Officer buy | $50k 15,625 shares | - | - | |
| 55Moderate | Kathy Lee-Sepsick Chief Executive Officer buy | $50k 15,625 shares | - | - | |
| 38Weak | Jeremy Alexander Sipos Chief Technology Officer buy | $10k 3,125 shares | - | - | |
| 38Weak | Jeffrey Gerald Mifek Chief Clinical-Medical Affairs buy | $10k 3,125 shares | - | - |
Transactions
The newest 50 of 67 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 24, 2026 | Alistair Milnes director | AGrant or award Stock Option (Right to Buy)derivative | +880 | $0.00 | $0 | 880 | Aug 11, 2026 |
| Jun 24, 2026 | Kenneth D. Eichenbaum director | AGrant or award Stock Option (Right to Buy)derivative | +880 | $0.00 | $0 | 880 | Aug 11, 2026 |
| Jul 6, 2026 | Jeffrey Gerald Mifek Chief Clinical-Medical Affairs | AGrant or award Stock Option (Right to Buy)derivative | +6,250 | $0.00 | $0 | 6,250 | Aug 11, 2026 |
| Aug 7, 2026 | John Charles Canning Chief Operating Officer | POpen-market purchase Common Stock | +4,375 | $3.20 | $14k | 4,375 | Aug 11, 2026 |
| Aug 7, 2026 | Jeffrey Gerald Mifek Chief Clinical-Medical Affairs | POpen-market purchase Common Stock | +3,125 | $3.20 | $10k | 3,125 | Aug 11, 2026 |
| Aug 7, 2026 | Dov Elefant Chief Financial Officer | POpen-market purchase Common Stock | +15,625 | $3.20 | $50k | 15,625 | Aug 11, 2026 |
| Aug 7, 2026 | Jeremy Alexander Sipos Chief Technology Officer | POpen-market purchase Common Stock | +3,125 | $3.20 | $10k | 3,125 | Aug 11, 2026 |
| Jun 24, 2026 | Charles Larsen director | AGrant or award Stock Option (Right to Buy)derivative | +880 | $0.00 | $0 | 880 | Aug 11, 2026 |
| Jun 24, 2026 | Edward R Uzialko director | AGrant or award Stock Option (Right to Buy)derivative | +880 | $0.00 | $0 | 880 | Aug 11, 2026 |
| Aug 7, 2026 | Kathy Lee-Sepsick Chief Executive Officer | POpen-market purchase Common Stock | +15,625 | $3.20 | $50k | 15,625 | Aug 11, 2026 |
| Aug 7, 2026 | Kathy Lee-Sepsick Chief Executive Officer | AGrant or award Common Stock Purchase Warrantderivative | +15,625 | - | - | 15,625 | Aug 11, 2026 |
| Aug 7, 2026 | Dov Elefant Chief Financial Officer | AGrant or award Common Stock Purchase Warrantderivative | +15,625 | - | - | 15,625 | Aug 11, 2026 |
| Aug 7, 2026 | Jeremy Alexander Sipos Chief Technology Officer | AGrant or award Common Stock Purchase Warrantderivative | +3,125 | - | - | 3,125 | Aug 11, 2026 |
| Aug 7, 2026 | John Charles Canning Chief Operating Officer | AGrant or award Common Stock Purchase Warrantderivative | +4,375 | - | - | 4,375 | Aug 11, 2026 |
| Aug 7, 2026 | Jeffrey Gerald Mifek Chief Clinical-Medical Affairs | AGrant or award Common Stock Purchase Warrantderivative | +3,125 | - | - | 3,125 | Aug 11, 2026 |
| Aug 7, 2026 | Dov Elefant Chief Financial Officer | AGrant or award Common Stock Purchase Warrant (Milestone)derivative | +15,625 | - | - | 15,625 | Aug 11, 2026 |
| Aug 7, 2026 | Kathy Lee-Sepsick Chief Executive Officer | AGrant or award Common Stock Purchase Warrant (Milestone)derivative | +15,625 | - | - | 15,625 | Aug 11, 2026 |
| Aug 7, 2026 | Jeremy Alexander Sipos Chief Technology Officer | AGrant or award Common Stock Purchase Warrant (Milestone)derivative | +3,125 | - | - | 3,125 | Aug 11, 2026 |
| Aug 7, 2026 | John Charles Canning Chief Operating Officer | AGrant or award Common Stock Purchase Warrant (Milestone)derivative | +4,375 | - | - | 4,375 | Aug 11, 2026 |
| Aug 7, 2026 | Jeffrey Gerald Mifek Chief Clinical-Medical Affairs | AGrant or award Common Stock Purchase Warrant (Milestone)derivative | +3,125 | - | - | 3,125 | Aug 11, 2026 |
| Mar 30, 2026 | John Charles Canning Chief Operating Officer | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Apr 1, 2026 |
| Mar 19, 2026 | Kenneth D. Eichenbaum director | AGrant or award Series D-1 Warrantsderivative | +102,366 | - | - | 102,366 | Mar 27, 2026 |
| Mar 19, 2026 | Dov Elefant Chief Financial Officer | AGrant or award Series D-1 Warrantsderivative | +34,122 | - | - | 34,122 | Mar 27, 2026 |
| Mar 19, 2026 | Charles Larsen director | AGrant or award Series D-1 Warrantsderivative | +34,122 | - | - | 34,122 | Mar 27, 2026 |
| Mar 19, 2026 | Kathy Lee-Sepsick Chief Executive Officer | AGrant or award Series D-1 Warrantsderivative | +68,244 | - | - | 68,244 | Mar 27, 2026 |
| Mar 18, 2026 | Kenneth D. Eichenbaum director | AGrant or award Stock Option (Right to Buy)derivative | +35,200 | $0.00 | $0 | 35,200 | Mar 20, 2026 |
| Feb 19, 2026 | Dov Elefant Chief Financial Officer | AGrant or award Restricted Stock Unitsderivative | +173,000 | $0.00 | $0 | 173,000 | Feb 20, 2026 |
| Feb 19, 2026 | Kathy Lee-Sepsick Chief Executive Officer | AGrant or award Restricted Stock Unitsderivative | +447,000 | $0.00 | $0 | 447,000 | Feb 20, 2026 |
| Feb 19, 2026 | Dov Elefant Chief Financial Officer | AGrant or award Restricted Stock Unitsderivative | +169,000 | $0.00 | $0 | 169,000 | Feb 20, 2026 |
| Feb 19, 2026 | Kathy Lee-Sepsick Chief Executive Officer | AGrant or award Restricted Stock Unitsderivative | +282,000 | $0.00 | $0 | 282,000 | Feb 20, 2026 |
| Feb 2, 2026 | Jeremy Alexander Sipos Chief Technology Officer | AGrant or award Restricted Stock Unitsderivative | +80,000 | $0.00 | $0 | 80,000 | Feb 17, 2026 |
| Nov 7, 2025 | Kathy Lee-Sepsick Chief Executive Officer | IDiscretionary transaction Senior Secured Convertible Notesderivative | - | - | - | - | Nov 19, 2025 |
| Nov 7, 2025 | Kathy Lee-Sepsick Chief Executive Officer | IDiscretionary transaction Series A-1 Warrantsderivative | +68,244 | - | - | 68,244 | Nov 19, 2025 |
| Nov 7, 2025 | Kathy Lee-Sepsick Chief Executive Officer | IDiscretionary transaction Series B-1 Warrantsderivative | +68,244 | - | - | 68,244 | Nov 19, 2025 |
| Nov 7, 2025 | Kathy Lee-Sepsick Chief Executive Officer | IDiscretionary transaction Series C-1 Warrantsderivative | +68,244 | - | - | 68,244 | Nov 19, 2025 |
| Nov 7, 2025 | Dov Elefant Chief Financial Officer | IDiscretionary transaction Senior Secured Convertible Notesderivative | - | - | - | - | Nov 12, 2025 |
| Nov 7, 2025 | Charles Larsen director | IDiscretionary transaction Senior Secured Convertible Notesderivative | - | - | - | - | Nov 12, 2025 |
| Nov 7, 2025 | Dov Elefant Chief Financial Officer | IDiscretionary transaction Series A-1 Warrantsderivative | +34,122 | - | - | 34,122 | Nov 12, 2025 |
| Nov 7, 2025 | Charles Larsen director | IDiscretionary transaction Series A-1 Warrantsderivative | +34,122 | - | - | 34,122 | Nov 12, 2025 |
| Nov 7, 2025 | Dov Elefant Chief Financial Officer | IDiscretionary transaction Series B-1 Warrantsderivative | +34,122 | - | - | 34,122 | Nov 12, 2025 |
| Nov 7, 2025 | Charles Larsen director | IDiscretionary transaction Series B-1 Warrantsderivative | +34,122 | - | - | 34,122 | Nov 12, 2025 |
| Nov 7, 2025 | Dov Elefant Chief Financial Officer | IDiscretionary transaction Series C-1 Warrantsderivative | +34,122 | - | - | 34,122 | Nov 12, 2025 |
| Nov 7, 2025 | Charles Larsen director | IDiscretionary transaction Series C-1 Warrantsderivative | +34,122 | - | - | 34,122 | Nov 12, 2025 |
| Aug 27, 2025 | Dov Elefant Chief Financial Officer | IDiscretionary transaction Common Stock | +38,828 | - | - | 58,436 | Aug 28, 2025 |
| Aug 27, 2025 | Kathy Lee-Sepsick Chief Executive Officer | IDiscretionary transaction Common Stock | +48,535 | - | - | 360,627 | Aug 28, 2025 |
| Aug 27, 2025 | Dov Elefant Chief Financial Officer | IDiscretionary transaction Common Warrants (right to buy)derivative | +38,828 | - | - | 38,828 | Aug 28, 2025 |
| Aug 27, 2025 | Kathy Lee-Sepsick Chief Executive Officer | IDiscretionary transaction Common Warrants (right to buy)derivative | +48,535 | - | - | 48,535 | Aug 28, 2025 |
| Jun 23, 2025 | Kelley Stinson Nicholas Chief Commercial Officer | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jul 1, 2025 |
| Jun 25, 2025 | Joshua Silverman director | AGrant or award Stock Option (Right to Buy)derivative | +17,600 | $0.00 | $0 | 17,600 | Jun 27, 2025 |
| Jun 25, 2025 | Charles Larsen director | AGrant or award Stock Option (Right to Buy)derivative | +17,600 | $0.00 | $0 | 17,600 | Jun 27, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- John Charles CanningChief Operating Officer
- Kenneth D. Eichenbaumdirector
- Dov ElefantChief Financial Officer
- Charles Larsendirector
- Kathy Lee-SepsickChief Executive Officer
- Jeffrey Gerald MifekChief Clinical-Medical Affairs
- Alistair Milnescoo, officer, director
- Kelley Stinson NicholasChief Commercial Officer
- Joshua Silvermanchair, officer, director, ceo, president
- Jeremy Alexander SiposChief Technology Officer
- Edward R Uzialkodirector
Questions about FEMY
Answered from the filings on this page, as of the latest one.
Are insiders buying FEMY?
As of Aug 11, 2026, SEC Form 4 filings show 5 open-market buys worth $134k by 5 insiders and 0 open-market sells worth $0 by 0 insiders at FEMASYS INC in the last 90 days, net +$134k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade FEMY on the open market?
John Charles Canning (Chief Operating Officer) bought $14k of FEMY on Aug 7, 2026 and filed the Form 4 on Aug 11, 2026. InsiderTell scored 43 (moderate), with 5 insiders on the same side within 14 days.
How many insiders file Form 4 at FEMASYS INC?
11 people have filed a Form 4 at FEMASYS INC, among them John Charles Canning (Chief Operating Officer), Kenneth D. Eichenbaum (director), Dov Elefant (Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.